SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-12-22
Accession Number: 0001213900-25-124553
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390025124553/filename1.htm

Chunk 8 of 51
Word Count: 1371
Character Count: 8824

Document Content:

trade policy have increased uncertainty in our industry, and any escalation in trade tensions could disrupt our supply chain, delay production timelines, or require costly modifications to sourcing and logistics strategies. The extent and duration of the tariffs and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand for our products in affected markets. Risks Related to Our Financial Condition and Capital Requirements We believe our current cash on hand will not be sufficient to fund our projected operating requirements for a period of twelve months from the issuance of our third quarter financial statements. This raises substantial doubt about our ability to continue as a going concern.

We believe that our current
cash on hand will not be sufficient to fund our projected operating requirements for a period of twelve months from the issuance of our
interim financial statements including in our quarterly report for the quarter ended September 30, 2025. This raises substantial doubt
about our ability to continue as a going concern and could materially limit our ability to raise additional funds through the issuance
of equity or debt securities or otherwise. If we cannot continue as a going concern, our investors may lose their entire investment in
our securities. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through debt or equity
financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available,
we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect
to our products.

Risks Related to this Offering and our Securities

Our executive officer,
directors and certain stockholders who are beneficial owners of more than 5% of our outstanding common shares possess the majority of
our voting power, and through this ownership, have the ability to control our Company and our corporate actions.

Our current executive officer
and directors hold approximately 22.20% of the issued and outstanding voting power of the Company’s outstanding shares. These persons
have a controlling influence in determining the outcome of any corporate transaction or other matters submitted to our stockholders for
approval, including mergers, consolidations and the sale of all or substantially all of our assets, election of directors, and other significant
corporate actions. As such, our directors and executive officer may have the power, acting alone or together, to prevent or cause a change
in control; therefore, without their consent we could be prevented from entering into transactions that could be beneficial to us. The
interests of our executive officer may give rise to a conflict of interest with the Company and the Company’s shareholders.

In addition, we have a number of stockholders who are beneficial owners
of more than 5% of our outstanding common shares, including one such shareholder who beneficially owns approximately 20.75% of our issued
and outstanding shares, and as such, also may have the ability to prevent us from entering into transactions that could be beneficial
to us and/or other shareholders. In addition, we have one additional non-affiliated stockholder who beneficially owns more than 5% of
our outstanding common shares. Although none of these non-affiliated stockholders currently have a controlling influence in determining
the outcome of any corporate transaction or other matters submitted to our stockholders for approval, including mergers, consolidations
and the sale of all or substantially all of our assets, election of directors, and other significant corporate actions, obtaining their
vote on certain matters may be necessary to effect certain actions that our management and directors otherwise deem to be in the best
interests of the Company.

Because we originally
became a public company through a reverse merger, we may continue to face challenges in attracting analyst coverage and institutional
investor interest.

We originally became a public
company through a reverse merger, rather than through a traditional underwritten initial public offering. Companies that enter the public
markets through reverse mergers often receive less attention from securities analysts and institutional investors, and such perceptions
may persist notwithstanding our uplisting to a national securities exchange. Because no investment bank acted as an underwriter in connection
with our becoming a public company, there is no broker-dealer with an inherent incentive to provide research coverage of our company.
The absence or limited availability of research coverage may reduce the visibility of our business in the public markets, which could
limit investor interest, reduce trading volume and adversely affect the market price and liquidity of our securities. Although our uplisting
may increase our visibility and improve access to a broader investor base, there can be no assurance that analysts will initiate or maintain
coverage of our company following the uplisting or that we will be able to attract institutional investors.

Our common stock is
subject to price volatility unrelated to us or our operations.

The market price of our common
stock could fluctuate substantially due to a variety of factors, including quarterly operating results of other companies in the same
industry, changes in general conditions in the economy and the financial markets, or other developments affecting the Company’s
competitors.

In addition, the securities
markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of
particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

Sales of a substantial
number of shares of our common stock, including shares that may be issued upon the exercise or conversion of outstanding securities or
become freely tradable under Rule 144, could cause the market price of our common stock to decline.

Out of the currently 54,218,813 outstanding shares of our common stock
of which only 18,200,592 were registered pursuant to a registration statements on Form S-1 with the SEC on June 5, 2020, the rest of our
shares of common stock that are currently outstanding are “restricted securities” within the meaning of Rule 144 under the
Securities Act. Restricted securities may be sold only pursuant to an effective registration statement under the Securities Act, in compliance
with Rule 144, or under another available exemption from registration, and in each case in compliance with applicable state securities
laws.

In general, once the applicable
holding period and other requirements of Rule 144 are satisfied, a person who is not an “affiliate” of our company and has
not been an affiliate during the preceding three months may resell restricted shares without limitation. Affiliates may resell restricted
shares in accordance with the volume, manner of sale and other limitations of Rule 144, which, among other things, generally limit the
number of shares that may be sold within any three-month period to the greater of 1% of the then-outstanding shares of our common stock
or the average weekly trading volume of our common stock on the principal trading market during the four calendar weeks immediately preceding
the sale.

If our existing stockholders,
particularly our affiliates or significant stockholders, sell substantial amounts of our common stock in the public market, or the perception
exists that such sales may occur, the market price of our common stock could decline. Any such sales, or the perception that they may
occur, could also impair our ability to raise additional capital through the sale of equity or equity-linked securities in the future.

If we fail to maintain
our listing on Nasdaq and our common stock once again becomes subject to the “penny stock” rules, it may be more difficult
for investors to sell their shares.

Prior to our proposed listing
on the Nasdaq, our common stock has been quoted on the OTCQB and, during that time, has been subject to the “penny stock”
rules under the Exchange Act. Securities subject to the penny stock rules are generally equity securities with a market price of less
than $5.00 per share that are not listed on a national securities exchange and that do not otherwise qualify for an exemption from the
penny stock definition.